Brandywine Global Investment Management LLC Acquires 9,786 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Brandywine Global Investment Management LLC grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 130,341 shares of the medical equipment provider’s stock after acquiring an additional 9,786 shares during the period. Brandywine Global Investment Management LLC owned about 0.07% of Zimmer Biomet worth $11,888,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Accent Capital Management LLC bought a new stake in Zimmer Biomet during the 1st quarter valued at approximately $35,000. Hilltop National Bank purchased a new stake in Zimmer Biomet during the 2nd quarter valued at approximately $42,000. True Wealth Design LLC raised its position in shares of Zimmer Biomet by 875.0% during the second quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 420 shares during the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of Zimmer Biomet in the first quarter worth $48,000. Finally, Brooklyn Investment Group boosted its position in shares of Zimmer Biomet by 45.9% during the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 145 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 3.4%

Shares of NYSE ZBH opened at $92.12 on Friday. The business’s 50 day moving average is $97.17 and its two-hundred day moving average is $96.78. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a 1-year low of $85.33 and a 1-year high of $114.44. The stock has a market capitalization of $18.26 billion, a P/E ratio of 22.41, a PEG ratio of 2.29 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the company earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 23.76%.

Insider Activity

In other news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.39% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a report on Thursday, September 18th. Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Rothschild & Co Redburn assumed coverage on Zimmer Biomet in a research report on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price on the stock. Royal Bank Of Canada cut their price target on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, November 6th. Finally, Canaccord Genuity Group reduced their price objective on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $109.00.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.